AbbVie Inc. (ABBV)
2025 Dividend Kings - Off To A Strong Start
The Dividend Kings are outperforming the S&P 500 in 2025, up 4% YTD versus 1.39% for SPY. Ten Dividend Kings have already achieved double-digit returns, led by National Fuel Gas (+22.08%) and Abbott Laboratories (+20.71%). 2025 Dividend growth is looking promising, with ABM Industries and Walmart leading with 17.78% and 15.69% increases, respectively.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates are shifting the risk/reward balance towards value stocks, making them more attractive compared to growth stocks. The AI revolution and liquidity improvements temporarily boosted growth stocks, but these tailwinds may not sustain long-term outperformance.
Why AbbVie Remains A Strong Buy For Long-Term Investors
Why AbbVie Remains A Strong Buy For Long-Term Investors
4 Seniors & Aging Demographics Stocks to Watch Right Now
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
How Dividend Investing Helps Parents Fund College Education Fees
More than half of parents in the United States emphasize paying for their child's college fees as a main concern. Start a UGMA custodial account early, and use the Dividend Growth Investing strategy to pay for college education and plan for retirement. By starting early and staying disciplined with the Dividend Growth Investing strategy, you can achieve Financial Freedom by your 40s.
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ability to generate steady revenue growth and strong free cash flows across different market cycles.
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of this article is to analyze their updates through Graham's framework for picking defensive stocks.
AbbVie Appears Ready To Move Higher
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq, shows robust growth. AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration.
Is AbbVie Stock a Buy Now?
AbbVie (ABBV -0.30%) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share (EPS), with both metrics exceeding initial guidance.
The Big 3: ABBV, EA, CEG
Today's Big 3 focuses on companies that couldn't be more different, but @ProsperTradingAcademy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's watching in AbbVie (ABBV), Electronic Arts (EA), and Constellation Energy (CEG).
AbbVie: An Undervalued Dividend Aristocrat
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets like immunology, neuroscience, and aesthetics, ensuring resilience and a wide moat. AbbVie consistently increases dividends, supported by solid financial health, robust cash reserves, and moderate leverage, reinforcing its attractiveness to investors.
